‘Vaccine business: A game of snakes-and-ladders’

Leading vaccine manufacturing honchos from around the world were seen on one stage at the 4th annual World Vaccine Summit 2014, which took place between March 5th & 6th, at the Hyderabad International Convention Centre, Hyderabad.

dr-krishnaella-cmd-bharatbiotech-dr-christianloucq-director-general-international-vaccine-institute

Dr Krishna Ella

The annual revenue of the global vaccine industry is expected to be USD 35 billion for 2014.

With Compounded Annual Growth Rate (CAGR) 11.5%, industry experts believe that the global vaccine is expected to be valued at USD 52 billion by 2016.

Though the vaccine industry looks promising, there seems to be inevitable challenges and road-blocks faced by many companies, including:

access to new technologies; regulatory challenges; vaccine clinical trials; obtaining patents and IP; limitations to development; production scaling; and manufacturing productivity.

Dr Krishna Ella, founder, Bharat Biotech, India, in his opening remarks said, "Everyone today is talking about innovation and costs. Over 15% of the world's population is accumulated in the developed world, and about 80% in the developing world. We spend less than 1% of our GDP on healthcare. Though the healthcare budget has come close to $5.5 billion, we spend only $100 million on vaccines."

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X